Drug Repurposing & Design to inhibit the SARS-CoV2 proteases (CoV2-Anti-protease project)
- Funded by Institut Pasteur International Network (IPIN)
- Total publications:240 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Funder
Institut Pasteur International Network (IPIN)Principal Investigator
N/A
Research Location
N/ALead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Identification of antiviral molecules targeting SARS-CoV2 proteases. Structures of the proteases will be used to screen large chemical libraries in complement of the FDA approved drugs. High Througput Screening (HTS) using dual mCherry-Nanoluc reporter cell lines can screen thousands of compounds. Combined with virtual screening this allows coverage of a large chemical space including purchasable compounds libraries. The best hits will be further validated on SARS-CoV-2 growth assays. Validated hits will guide optimization of compounds.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC